Lliss Nafdac Blacklist Aveo Pharmaceuticals, prohibits dangerous combination of opiates

The National Agency for Food and Drug Administration and Control (Nafdac) has officially included in the black list of Aveo Pharmaceuticals Pvt Limited, a pharmaceutical company based in India managed by Vinod Sharma, for its involvement in illegal production and exporting dangerous opioid combinations for Western Africa.

An investigation by the BBC world service discovered that Aveo Pharmaceuticals has produced and exporting non -approved drugs, including Tafrodol and Royal 225, which contain a mix of tapentadolo, a powerful opiate and Carisoprodolo, a prohibited relaxing muscle.

According to the general manager of the agency, Prof. Mojisola Christiah Adeyeye, these substances had been linked to addiction, respiratory discomfort, convulsions and even death.

According to reports, the drugs flooded the streets of Ghana, Nigeria and Ivory Coast, fueling opiate dependence in the region.

He underlined that he had never approved Tafrodol, Royal 225 or any tramadolo product greater than 100 mg for distribution in Nigeria.

Citing the Nafdac Act and the Falset and Fake Drugs Act, the agency has taken measures to prevent any future recording of products from Aveo Pharmaceuticals.

A secret investigation revealed that Vinod Sharma personally confirmed the large -scale exports of these drugs to West Africa for illegal distribution.

Although they are without global license, the drugs have become popular opioids of the street thanks to their convenience and widespread availability.

Nafdac has increased the application measures, collaborating with security agencies to repress illegal pharmaceutical sales and prevent the smuggling of these substances through the borders of Nigeria.

The agency reiterated its commitment to protect public health through severe regulatory practices, inspections and surveillance to eliminate false and poor drugs from circulation.

“The public is invited to avoid unregistered drugs and report any suspicious pharmaceutical activities.

“Nafdac remains still in his mission to safeguard the health of the Nigerians,” said the agency.